SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) AND ANTI-CANCER AGENT

PROBLEM TO BE SOLVED: To provide a formulation comprising a multi-vesicular liposome and MTX.SOLUTION: The present invention provides formulations comprising a multi-vesicular liposome and MTX, the administration of which results in a Cof MTX between 5% and 50% of the Cof an immediate release dosage...

Full description

Saved in:
Bibliographic Details
Main Authors WILLIAM LAMBERT, BENJAMIN LI, LOIS GIBSON, ZHU LIANGJIN, LOUIE DANIEL GARCIA
Format Patent
LanguageEnglish
Japanese
Published 13.04.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a formulation comprising a multi-vesicular liposome and MTX.SOLUTION: The present invention provides formulations comprising a multi-vesicular liposome and MTX, the administration of which results in a Cof MTX between 5% and 50% of the Cof an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. The present invention also provides a method for treating autoimmune diseases and cancer by administering these formulations of MTX. The present invention also provides a method for treating autoimmune diseases, the method comprising administering the MTX-MVL formulation to a subject in need thereof.SELECTED DRAWING: None 【課題】多胞リポソームおよびＭＴＸを含む製剤を提供すること。【解決手段】多胞リポソームおよびＭＴＸを含む製剤が開示され、それの投与が、即効型剤形のＭＴＸのＣｍａｘの５％〜５０％の間のＭＴＸのＣｍａｘを生じ、それの持続期間が約１日間〜約３０日間続く。これらのＭＴＸ製剤を投与することにより、自己免疫疾患および癌を処置する方法もまた開示されている。別の実施形態は、自己免疫疾患を処置するための方法であって、本ＭＴＸ−ＭＶＬ製剤を、それを必要とする被験体に投与することを含む方法を提供する。【選択図】なし
Bibliography:Application Number: JP20170013045